We are live on ! Find out more
IDXG

Interpace Biosciences, Inc. Common Stock
IDXG

Delisted

IDXG was delisted on the 24th of February, 2021.

Back to rankings

18 hedge funds and large institutions have $5.26M invested in Interpace Biosciences, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 1

10% less funds holding

Funds holding: 20 → 18 (-2)

24% less capital invested

Capital invested by funds: $6.96M → $5.26M (-$1.69M)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
18
Holders Change
-2
Holders Change %
-10%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
9
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$234K
2
EIM
Essex Investment Management
Massachusetts
+$201K
3
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
+$16.2K
4
VF
Virtu Financial
New York
+$15.5K
5
MWM
Merriman Wealth Management
Washington
+$14.6K

Top Sellers

Rank Fund Capital Flow
1
SCM
Sio Capital Management
New York
-$1.32M
2
SSA
Schonfeld Strategic Advisors
New York
-$320K
3
Citadel Advisors
Citadel Advisors
Florida
-$26K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$21K
5
UBS Group
UBS Group
Switzerland
-$4.52K

IDXG Hedge Fund Activity: Q2 2019 in Review

18 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q2 2019, worth a combined $5.26M — down 24% from $6.96M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of IDXG and 2 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 9 added.

The largest buyer was Stonepine Capital Management, adding an estimated $234K. The largest seller was Sio Capital Management, exiting entirely with an estimated $1.32M sold.

  • 18 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q2 2019, down from 20 in Q1 2019.
  • Funds reported $5.26M of Interpace Biosciences, Inc. Common Stock stock for Q2 2019, down 24% quarter-over-quarter.
  • 2 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q2 2019 and 4 closed out, a net change of -2 holders.
  • The largest Interpace Biosciences, Inc. Common Stock buyer in Q2 2019 was Stonepine Capital Management, an estimated $234K added.
  • The largest Interpace Biosciences, Inc. Common Stock seller in Q2 2019 was Sio Capital Management, an estimated $1.32M sold.

Based on aggregated 13F filings for Q2 2019.